NASDAQ:VRTX Vertex Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vertex Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $265.39 -6.07 (-2.24 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$257.42Now: $265.39▼$273.5950-Day Range$255.65MA: $269.86▼$281.8952-Week Range$165.23Now: $265.39▼$306.08Volume2.18 million shsAverage Volume1.76 million shsMarket Capitalization$69.13 billionP/E Ratio33.51Dividend YieldN/ABeta0.85 ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna Therapeutics, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; and Kymera Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingVertex Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.76, and is based on 20 buy ratings, 8 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $296.15, Vertex Pharmaceuticals has a forecasted upside of 11.6% from its current price of $265.39.Amount of Analyst CoverageVertex Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.2 Community Rank Outperform VotesVertex Pharmaceuticals has received 1,430 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVertex Pharmaceuticals has received 790 “underperform” votes. (Add your “underperform” vote.)Community SentimentVertex Pharmaceuticals has received 64.41% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals and other stocks. Vote “Outperform” if you believe VRTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VRTX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVertex Pharmaceuticals does not currently pay a dividend.Dividend GrowthVertex Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vertex Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,836,329.00 in company stock.Percentage Held by InsidersOnly 0.48% of the stock of Vertex Pharmaceuticals is held by insiders.Percentage Held by Institutions92.17% of the stock of Vertex Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vertex Pharmaceuticals are expected to grow by 8.75% in the coming year, from $8.46 to $9.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vertex Pharmaceuticals is 33.51, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 18.90.Price to Earnings Ratio vs. SectorThe P/E ratio of Vertex Pharmaceuticals is 33.51, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.75.Price to Earnings Growth RatioVertex Pharmaceuticals has a PEG Ratio of 1.54. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioVertex Pharmaceuticals has a P/B Ratio of 11.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.64 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:VRTX Previous Symbol CUSIP92532F10 CIK875320 Webwww.vrtx.com Phone617-341-6100Debt Debt-to-Equity Ratio0.07 Current Ratio3.72 Quick Ratio3.60Price-To-Earnings Trailing P/E Ratio33.51 Forward P/E Ratio31.37 P/E Growth1.54 Sales & Book Value Annual Sales$4.16 billion Price / Sales16.61 Cash Flow$4.90 per share Price / Cash Flow54.13 Book Value$23.66 per share Price / Book11.22Profitability EPS (Most Recent Fiscal Year)$4.29 Net Income$1.18 billion Net Margins38.51% Return on Equity28.55% Return on Assets20.68%Miscellaneous Employees3,000 Outstanding Shares260,467,000Market Cap$69.13 billion Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $265.39 -6.07 (-2.24 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive VRTX News and Ratings via Email Sign-up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter. Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions How has Vertex Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)? Vertex Pharmaceuticals' stock was trading at $220.34 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VRTX stock has increased by 20.4% and is now trading at $265.39. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Vertex Pharmaceuticals? 29 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 8 hold ratings, 20 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vertex Pharmaceuticals. When is Vertex Pharmaceuticals' next earnings date? Vertex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Vertex Pharmaceuticals. How were Vertex Pharmaceuticals' earnings last quarter? Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) posted its quarterly earnings results on Thursday, July, 30th. The pharmaceutical company reported $2.61 EPS for the quarter, topping the Zacks' consensus estimate of $1.75 by $0.86. The pharmaceutical company earned $1.52 billion during the quarter, compared to analysts' expectations of $1.41 billion. Vertex Pharmaceuticals had a return on equity of 28.55% and a net margin of 38.51%. View Vertex Pharmaceuticals' earnings history. How will Vertex Pharmaceuticals' stock buyback program work? Vertex Pharmaceuticals declared that its Board of Directors has authorized a stock repurchase program on Wednesday, July 31st 2019, which allows the company to buyback $500,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 1.2% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's leadership believes its shares are undervalued. What guidance has Vertex Pharmaceuticals issued on next quarter's earnings? Vertex Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Thursday, July, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $5.7-5.9 billion, compared to the consensus revenue estimate of $5.73 billion. What price target have analysts set for VRTX? 29 Wall Street analysts have issued 12-month price objectives for Vertex Pharmaceuticals' shares. Their forecasts range from $230.00 to $340.00. On average, they anticipate Vertex Pharmaceuticals' stock price to reach $296.15 in the next twelve months. This suggests a possible upside of 11.6% from the stock's current price. View analysts' price targets for Vertex Pharmaceuticals. Are investors shorting Vertex Pharmaceuticals? Vertex Pharmaceuticals saw a drop in short interest during the month of August. As of August 14th, there was short interest totaling 3,360,000 shares, a drop of 17.0% from the July 30th total of 4,050,000 shares. Based on an average daily volume of 1,720,000 shares, the short-interest ratio is presently 2.0 days. View Vertex Pharmaceuticals' Short Interest. Who are some of Vertex Pharmaceuticals' key competitors? Some companies that are related to Vertex Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Immunomedics (IMMU), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Repligen (RGEN) and Exelixis (EXEL). View all competitors. What other stocks do shareholders of Vertex Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Bsc DEDSP (SBS), Alibaba Group (BABA), Gilead Sciences (GILD), Advanced Micro Devices (AMD), salesforce.com (CRM), Micron Technology (MU), Netflix (NFLX), Paypal (PYPL) and Intel (INTC). Who are Vertex Pharmaceuticals' key executives? Vertex Pharmaceuticals' management team includes the following people: Mr. Jeffrey Marc Leiden, Chairman, CEO & Pres (Age 63)Mr. Michael J. Parini, Exec. VP and Chief Legal & Admin. Officer (Age 44)Mr. Amit K. Sachdev, Exec. VP & Chief Regulatory Officer (Age 51)Mr. Stuart A. Arbuckle, Exec. VP & Chief Commercial Officer (Age 53)Dr. Jeffrey A. Chodakewitz, Sr. Advisor (Age 63) What is Vertex Pharmaceuticals' stock symbol? Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX." Who are Vertex Pharmaceuticals' major shareholders? Vertex Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.79%), Vanguard Group Inc. (8.01%), FMR LLC (7.40%), Jennison Associates LLC (1.70%), Nuveen Asset Management LLC (1.34%) and Bank of New York Mellon Corp (0.96%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, Thomas Graney, William D Young and Yuchun Lee. View institutional ownership trends for Vertex Pharmaceuticals. Which major investors are selling Vertex Pharmaceuticals stock? VRTX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Assenagon Asset Management S.A., TimesSquare Capital Management LLC, Holocene Advisors LP, Bellevue Group AG, Goldman Sachs Group Inc., Toronto Dominion Bank, and Candriam Luxembourg S.C.A.. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, William D Young, and Yuchun Lee. View insider buying and selling activity for Vertex Pharmaceuticals. Which major investors are buying Vertex Pharmaceuticals stock? VRTX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., California Public Employees Retirement System, Nuveen Asset Management LLC, APG Asset Management N.V., GQG Partners LLC, First Trust Advisors LP, Vanguard Group Inc., and Robeco Institutional Asset Management B.V.. View insider buying and selling activity for Vertex Pharmaceuticals. How do I buy shares of Vertex Pharmaceuticals? Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Vertex Pharmaceuticals' stock price today? One share of VRTX stock can currently be purchased for approximately $265.39. How big of a company is Vertex Pharmaceuticals? Vertex Pharmaceuticals has a market capitalization of $69.13 billion and generates $4.16 billion in revenue each year. The pharmaceutical company earns $1.18 billion in net income (profit) each year or $4.29 on an earnings per share basis. Vertex Pharmaceuticals employs 3,000 workers across the globe. What is Vertex Pharmaceuticals' official website? The official website for Vertex Pharmaceuticals is www.vrtx.com. How can I contact Vertex Pharmaceuticals? Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at 617-341-6100 or via email at [email protected] This page was last updated on 9/20/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
